Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT04906993
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Relative Bioavailability Study of SHR3680
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04903158
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China
A Trial of HR19042 Capsule in Healthy Chinese Subjects
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04887532
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 692
- Registration Number
- NCT04885218
- Locations
- 🇨🇳
Beijing Anzhen hospital, Beijing, Beijing, China
A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04884009
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT04869488
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04867343
- Locations
- 🇨🇳
General Hospital, Tianjin Medical University, Tianjin, Tianjin, China
A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04862884
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT04862091
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Trial of SHR0410 Injection for the Treatment of Pain After Endoscopic Surgery of the Lower Abdominal
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT04852003
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
© Copyright 2024. All Rights Reserved by MedPath